Human CD40 / TNFRSF5 Protein, His Tag (MALS verified)
分子別名(Synonym)
CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD40, His Tag (CD0-H5228) is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Arg 193 (Accession # P25942-1).
Predicted N-terminus: Glu 21
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 21.1 kDa. The protein migrates as 29-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
CD40也稱為TNFRSF5、Bp50、CDW40、MGC9013、TNFRSF5和p50,是TNF受體超家族的成員,是單跨膜糖蛋白,在介導(dǎo)各種免疫和炎癥反應(yīng)中起著至關(guān)重要的作用,包括T細(xì)胞依賴性免疫球蛋白類轉(zhuǎn)換、記憶B細(xì)胞發(fā)育和生發(fā)中心形成。CD40是一種在抗原呈遞細(xì)胞上發(fā)現(xiàn)的共刺激蛋白,是其激活所必需的。TH細(xì)胞上的CD154(CD40L)與CD40的結(jié)合激活抗原呈遞細(xì)胞并誘導(dǎo)各種下游效應(yīng)。CD40在細(xì)胞外結(jié)構(gòu)域含有4個(gè)富含半胱氨酸的重復(fù)序列,在B細(xì)胞、樹突狀細(xì)胞、巨噬細(xì)胞、內(nèi)皮細(xì)胞和幾種腫瘤細(xì)胞系中表達(dá)。細(xì)胞外結(jié)構(gòu)域具有富含半胱氨酸的重復(fù)區(qū),這是TNF超家族許多受體的特征。CD40與其配體CD40L的相互作用導(dǎo)致CD40分子聚集,進(jìn)而與細(xì)胞質(zhì)成分相互作用以啟動(dòng)信號(hào)通路。早期對(duì)CD40-CD40L系統(tǒng)的研究揭示了其在體液免疫中的作用。CD40缺陷導(dǎo)致高IgM免疫缺陷3型(HIGM3),這是一種常染色體隱性遺傳疾病,其特征是B細(xì)胞無法進(jìn)行同種型轉(zhuǎn)換,也無法產(chǎn)生抗體特異性免疫反應(yīng),并且缺乏生發(fā)中心形成。
關(guān)鍵字: CD40;CD40蛋白;CD40重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。